Hexarelin · Research brief

What’s the Half-Life of Hexarelin? (Peptide Pharmacology)

Real Peptides Research TeamEditorial

Updated June 15, 20269 min read

49 WORDS

Short answer

(Peptide Pharmacology) Most peptide researchers focus on plasma half-life when timing injections. But with hexarelin, that number misleads more than it informs. The peptide clears from detectable plasma levels within 70–80 minutes, yet its effect on pituitary GH (growth hormone) secretion persists for four to six hours after administration.

Key takeaways

Hexarelin has a plasma elimination half-life of 70–80 minutes, but GH pulsatility persists 4–6 hours post-injection due to sustained GHS-R1a receptor occupancy.
Subcutaneous administration delays peak plasma concentration to 20–30 minutes but produces identical terminal half-life and more physiological GH pulse shape compared to IV bolus.
Twice-daily dosing (10–12 hours apart) prevents overlapping GH pulses and reduces the risk of acute receptor desensitisation during short-term protocols.
Hexarelin produces the highest-amplitude GH peaks among peptide secretagogues but develops significant tachyphylaxis after 4–8 weeks of daily use. Ipamorelin maintains response longer.
Functional half-life (time for GH to return halfway to baseline) exceeds plasma half-life by a factor of 3–4, making pharmacodynamic duration the critical timing variable in protocol design.
Receptor desensitisation risk makes hexarelin best suited for short-duration studies (2–4 weeks) focused on peak GH capacity rather than chronic metabolic intervention.

What's the Half-Life of Hexarelin? (Peptide Pharmacology)

Most peptide researchers focus on plasma half-life when timing injections. But with hexarelin, that number misleads more than it informs. The peptide clears from detectable plasma levels within 70–80 minutes, yet its effect on pituitary GH (growth hormone) secretion persists for four to six hours after administration. This disconnect between pharmacokinetic clearance and pharmacodynamic effect matters when designing research protocols, spacing doses, and interpreting outcome data from multi-week studies.

We've worked with research teams across institutions running hexarelin protocols, and the gap between the 70-minute clearance number and the actual duration of biological effect is where most design errors occur. The peptide's mechanism. Direct binding to GHS-R1a (growth hormone secretagogue receptor type 1a) in the anterior pituitary. Doesn't turn off the instant plasma concentration drops below detection thresholds.

What's the half-life of hexarelin in human plasma?

Hexarelin has a plasma elimination half-life of approximately 70–80 minutes following subcutaneous or intravenous administration, meaning systemic concentrations fall to half their peak within that window. However, the peptide's effect on growth hormone secretion. Mediated through pituitary GHS-R1a receptor activation. Persists for 4–6 hours post-injection, creating a functional duration that significantly exceeds plasma detectability. This pharmacodynamic window determines optimal dosing intervals in research protocols more accurately than clearance kinetics alone.

The 70-minute plasma half-life tells you when hexarelin becomes undetectable in serum assays. It doesn't tell you when receptor occupancy ends or when GH pulsatility returns to baseline. That distinction reshapes how protocols are structured. This article covers the receptor binding mechanism that extends biological duration beyond clearance, how subcutaneous versus intravenous routes alter absorption kinetics, what desensitisation timelines mean for multi-week studies, and how hexarelin's brief plasma window compares to other GH secretagogues like GHRP-2 and ipamorelin.

Hexarelin Receptor Binding and GH Pulse Duration

Hexarelin functions as a synthetic hexapeptide ghrelin mimetic, binding with high affinity to GHS-R1a receptors concentrated in the anterior pituitary somatotrophs. The cells responsible for pulsatile growth hormone secretion. Receptor occupancy triggers intracellular calcium mobilisation and cAMP elevation, which drive GH release within 20–30 minutes of administration. The critical detail: receptor-mediated GH pulsatility doesn't shut off immediately when plasma hexarelin concentration falls below detection limits.

Studies using serial GH sampling post-hexarelin administration consistently show elevated GH levels persisting 4–6 hours after injection, well beyond the 70–80 minute plasma half-life. This extended effect reflects sustained receptor activation. Hexarelin's affinity for GHS-R1a creates receptor occupancy that outlasts systemic clearance. The peptide dissociates slowly from the receptor complex, meaning biological activity continues even as serum concentrations approach zero.

In practical terms: a researcher administering 100mcg hexarelin subcutaneously at 08:00 will see peak GH elevation around 08:30, but GH levels won't return to baseline until approximately 12:00–14:00. Plasma hexarelin, meanwhile, becomes undetectable by 10:00. This four-hour lag between clearance and effect termination is why twice-daily dosing protocols (morning and evening) remain the standard. Spacing doses 10–12 hours apart prevents overlapping GH pulses that could trigger receptor desensitisation.

Our team has reviewed this pattern across institutions running comparative GH secretagogue studies. The functional half-life. Defined as the time required for GH levels to return halfway to baseline. Consistently exceeds the plasma elimination half-life by a factor of three to four.

Subcutaneous vs Intravenous Administration Kinetics

Route of administration alters hexarelin's absorption profile but not its elimination half-life once systemic circulation is reached. Intravenous bolus delivers immediate peak plasma concentration (Cmax) within 5–10 minutes, followed by rapid two-phase elimination. An initial distribution phase (alpha half-life ~15 minutes) and a terminal elimination phase (beta half-life 70–80 minutes). Subcutaneous injection delays Cmax to approximately 20–30 minutes post-administration as the peptide diffuses from the injection depot into capillaries, but the terminal elimination half-life remains identical at 70–80 minutes.

The GH response curve, however, shifts slightly between routes. IV administration produces a sharper, higher-amplitude GH peak (often 15–25% higher than subcutaneous), but the overall area under the curve (AUC) for GH secretion across the 6-hour observation window differs by less than 10%. Subcutaneous delivery generates a more physiological, sustained GH pulse that researchers often prefer when mimicking endogenous pulsatile patterns.

Intramuscular administration. Occasionally used in veterinary research but rare in human protocols. Produces kinetics intermediate between IV and subcutaneous routes: Cmax at 15–20 minutes, terminal half-life unchanged. Regardless of route, the peptide's effect on GH pulsatility persists 4–6 hours, reinforcing that receptor pharmacodynamics govern functional duration more than absorption speed.

Here's what we've learned through protocol optimisation work: subcutaneous remains the preferred route for multi-week studies because it reduces peak-trough variability, lowers the risk of acute receptor saturation, and better sustains physiological GH pulsatility. IV boluses serve research questions focused on peak GH capacity testing or receptor reserve assessment. Not chronic administration studies.

Hexarelin Half-Life: Peptide Comparison

Understanding what's the half-life of hexarelin requires context against other growth hormone secretagogues used in research. Each peptide's clearance kinetics and receptor interaction profile determine optimal dosing intervals.

Peptide	Plasma Half-Life	GH Pulse Duration	Receptor Selectivity	Desensitisation Risk	Professional Assessment
Hexarelin	70–80 minutes	4–6 hours	High affinity for GHS-R1a; moderate cortisol/prolactin elevation	High. Significant tachyphylaxis after 4–8 weeks daily dosing	Best for short-term GH peak assessment; chronic use limited by receptor desensitisation
GHRP-2	20–30 minutes	2–3 hours	Moderate GHS-R1a affinity; stronger cortisol co-secretion	Moderate. Some attenuation after 8–12 weeks	Shorter functional window requires more frequent dosing; cortisol spike complicates metabolic interpretation
Ipamorelin	90–120 minutes	3–4 hours	High GHS-R1a selectivity; minimal cortisol/prolactin effect	Low. Sustained response over 12+ weeks	Longer half-life with cleaner GH selectivity; preferred for extended protocols
CJC-1295 (DAC)	6–8 days	7–10 days	Long-acting GHRH analogue; different mechanism (GHRH receptor)	Very low. Physiological pulsatility maintained	Not a ghrelin mimetic; creates sustained GH elevation without discrete pulses
MK-677 (oral)	4–6 hours (active metabolite)	24 hours	Non-peptide ghrelin mimetic; continuous receptor activation	Moderate. Some studies show maintained response at 12 months	Oral bioavailability advantage; constant GH elevation rather than pulsatile

Hexarelin's 70-minute plasma clearance sits between GHRP-2 (shorter) and ipamorelin (longer), but its 4–6 hour GH pulse duration exceeds GHRP-2 significantly. The trade-off: hexarelin produces the most robust GH peak of any peptide secretagogue at equivalent molar doses. Often 30–50% higher than ipamorelin. But receptor desensitisation develops faster. Studies document significant attenuation of the GH response after 4–8 weeks of daily hexarelin administration, whereas ipamorelin maintains 70–80% of initial response at 12 weeks.

For researchers designing studies: hexarelin works best in short-duration protocols (2–4 weeks) where maximum GH stimulation is the primary endpoint. Ipamorelin suits extended metabolic studies where sustained, moderate GH elevation without tachyphylaxis is required. GHRP-2's shorter functional window makes it less practical for twice-daily protocols. The comparison underscores that what's the half-life of hexarelin in plasma (70–80 minutes) matters far less than the 4–6 hour receptor-mediated effect when selecting the right peptide for a research question.

What If: Hexarelin Dosing Scenarios

What If I Dose Hexarelin Three Times Daily Instead of Twice?

Triple-daily dosing accelerates receptor desensitisation without proportionally increasing cumulative GH secretion. Spacing doses 6–8 hours apart creates overlapping GH pulses. The second injection lands before GH from the first dose returns to baseline, leading to sustained receptor occupancy that triggers downregulation of GHS-R1a expression within 7–14 days. Studies using frequent dosing schedules (3+ times daily) show 40–60% attenuation of the GH response within two weeks, compared to 15–25% attenuation with twice-daily protocols over the same period. Stick to 10–12 hour intervals unless the research design explicitly tests desensitisation kinetics.

What If Hexarelin Is Stored at Room Temperature Before Reconstitution?

Lyophilised hexarelin powder remains stable at room temperature (20–25°C) for several months when stored in sealed vials protected from light and moisture. Peptide degradation accelerates above 25°C or in humid conditions. Prolonged exposure to 30°C+ can cause oxidation of methionine residues and structural destabilisation. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. A single brief temperature excursion (e.g., 2–4 hours at room temperature during transport) typically doesn't compromise potency, but repeated cycling between temperatures degrades the peptide faster than continuous refrigeration.

What If GH Response Diminishes After Two Weeks of Daily Dosing?

Reduced GH response after 10–14 days of daily hexarelin administration indicates receptor desensitisation. A well-documented phenomenon with this peptide. The mechanism involves downregulation of GHS-R1a receptor density in pituitary somatotrophs due to chronic stimulation. A 5–7 day washout period typically restores 60–80% of initial receptor sensitivity, though full recovery may require 14–21 days without exposure. Cycling protocols (e.g., 5 days on, 2 days off, or 2 weeks on, 1 week off) can extend usable study duration but complicate interpretation of cumulative metabolic endpoints. If sustained GH elevation is required beyond four weeks, consider switching to ipamorelin or MK-677, both of which exhibit lower desensitisation rates.

The Clinical Truth About Hexarelin Half-Life Misinterpretation

Here's the honest answer: the 70-minute plasma half-life is the number most researchers cite, but it's nearly useless for protocol design. What matters is the 4–6 hour window of GH pulsatility. That's the functional half-life driving metabolic effects, receptor occupancy, and downstream signalling through IGF-1 pathways. Focusing on clearance kinetics instead of receptor pharmacodynamics leads to dosing errors that either waste peptide (dosing too frequently before the prior pulse resolves) or miss optimal timing windows (spacing doses so far apart that baseline GH troughs extend unnecessarily).

The 70-minute number comes from pharmacokinetic assays measuring serum peptide concentration. It tells you when hexarelin becomes undetectable in blood, not when its biological effect ends. GH secretion peaks 20–30 minutes post-injection, remains elevated for 3–4 hours, and doesn't return fully to baseline until 5–6 hours post-dose. Serial GH sampling studies published in the Journal of Clinical Endocrinology & Metabolism confirm this repeatedly. If you're timing injections based on plasma clearance, you're solving the wrong problem.

The desensitisation issue compounds this. Hexarelin's high receptor affinity. The same property that makes it the most potent GH secretagogue per microgram. Drives faster tachyphylaxis than lower-affinity peptides. Researchers chasing maximum GH peaks often dose daily for weeks, then wonder why response drops 50% by week three. The receptor doesn't care about your study timeline. Chronic overstimulation triggers protective downregulation. Cycling or switching peptides isn't a workaround; it's the protocol.

Our team has seen research groups waste entire study cohorts because they mistook plasma half-life for functional duration. The 70-minute number belongs in pharmacokinetic textbooks, not dosing schedules. Design around the 4–6 hour GH pulse, space injections 10–12 hours apart, and plan washout periods before receptor sensitivity becomes the limiting variable. That's the clinical reality hexarelin demands.

Hexarelin remains a powerful tool for GH research. When half-life is interpreted correctly. The 70–80 minute plasma clearance is a distraction. The 4–6 hour receptor-mediated GH pulse is the number that determines whether your protocol works or fails. Institutions sourcing research-grade peptides need suppliers who understand this distinction and provide material with verified amino-acid sequencing and consistent batch purity. Variables that directly affect receptor binding affinity and, by extension, functional half-life reproducibility. Poor-quality hexarelin doesn't just reduce GH response amplitude; it introduces variability in clearance kinetics and receptor interaction that makes interpreting half-life data impossible. Precision synthesis and third-party purity verification aren't luxuries in peptide research. They're the baseline requirements for reproducible pharmacodynamic outcomes.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Hexarelin clears from detectable plasma levels within 6–8 hours post-injection, with a terminal elimination half-life of 70–80 minutes. However, the peptide’s biological effect on growth hormone secretion persists for 4–6 hours due to sustained receptor occupancy at pituitary GHS-R1a sites. Complete metabolic clearance — including inactive metabolites — occurs within 24 hours, though GH-mediated downstream effects (elevated IGF-1, lipolysis) may continue for 48–72 hours depending on baseline metabolic state.

Hexarelin is detectable in urine and blood samples using liquid chromatography-mass spectrometry (LC-MS/MS) methods employed by WADA-accredited laboratories. Detection windows vary by sample type: blood testing can identify hexarelin for up to 12–24 hours post-administration, while urine testing extends the window to 48–72 hours depending on dose and individual renal clearance rates. The peptide is prohibited under WADA regulations as a growth hormone secretagogue (S2 category), and its use triggers disqualification in competitive sports.

Twice-daily dosing spaced 10–12 hours apart (e.g., 08:00 and 20:00) optimises GH pulsatility without triggering rapid receptor desensitisation. This interval allows GH levels to return near baseline between doses, preventing sustained receptor occupancy that accelerates tachyphylaxis. Dosing three or more times daily creates overlapping GH pulses and reduces response amplitude by 40–60% within two weeks. Single daily dosing works for short-term peak GH assessment but underutilises the peptide’s 4–6 hour functional window for metabolic studies.

Endogenous ghrelin has an extremely short plasma half-life of 10–30 minutes due to rapid enzymatic degradation by plasma esterases, which cleave the acyl modification required for receptor binding. Hexarelin, as a synthetic analogue with D-amino acid substitutions, resists enzymatic breakdown and achieves a 70–80 minute plasma half-life — roughly three times longer than native ghrelin. This stability allows practical dosing intervals and sustained GH stimulation that endogenous ghrelin’s pulsatile, meal-triggered secretion pattern cannot maintain.

The pharmacokinetic half-life (70–80 minutes) remains constant with repeated administration — clearance mechanisms don’t adapt to chronic peptide exposure. What changes is the pharmacodynamic response: receptor desensitisation reduces GH secretion amplitude by 30–50% after 4–8 weeks of daily dosing, even though plasma hexarelin concentration curves remain identical. This disconnect means the peptide clears at the same rate, but progressively fewer receptors remain available to bind and trigger GH release as study duration extends.

Renal function is the primary determinant of hexarelin clearance — peptides are eliminated predominantly through glomerular filtration and tubular secretion. Individuals with impaired kidney function (eGFR below 60 mL/min/1.73m²) show 40–70% longer plasma half-lives and delayed GH pulse resolution. Age, body composition, and hepatic function have minimal direct effect on hexarelin clearance, though obesity can alter volume of distribution and delay subcutaneous absorption. Genetic variation in GHS-R1a receptor expression affects response amplitude but not elimination kinetics.

Lyophilised hexarelin should be stored at −20°C (freezer) for long-term stability exceeding 12–24 months, or at 2–8°C (refrigerator) for up to 6 months when sealed and protected from light. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days — peptide degradation accelerates at room temperature, reducing potency by 10–20% per week. Temperature excursions above 8°C denature the peptide structure, altering both receptor binding affinity and clearance kinetics in ways that invalidate half-life data.

Hexarelin binds GHS-R1a receptors with exceptionally high affinity (Kd ~0.7 nM), creating prolonged receptor occupancy that triggers compensatory downregulation of receptor expression on pituitary cell surfaces. This adaptive response — mediated through internalisation and degradation of ligand-receptor complexes — occurs faster with high-affinity ligands than with moderate-affinity peptides like ipamorelin (Kd ~2.6 nM). Additionally, hexarelin stimulates cortisol and prolactin co-secretion through non-GHS-R1a pathways, potentially contributing to central negative feedback that further accelerates GH response attenuation.

Researchers have explored albumin-binding modifications and PEGylation (polyethylene glycol conjugation) to extend hexarelin’s plasma half-life, with limited success. PEGylated analogues show 3–5 times longer plasma residence (4–6 hours vs 70 minutes), but reduced receptor binding affinity offsets the pharmacokinetic gain — GH response amplitude drops 30–50% compared to native hexarelin. Sustained-release depot formulations exist experimentally but aren’t commercially available for research use. The current consensus: hexarelin’s brief half-life is intrinsic to its structure, and extending it requires trade-offs in potency or selectivity.

Administering hexarelin during endogenous GH secretion (typically during deep sleep, 1–3 hours post-sleep onset) produces additive but not synergistic effects — the exogenous peptide triggers a separate, overlapping GH pulse rather than amplifying the ongoing physiological release. Total GH AUC increases, but peak amplitude may be blunted compared to dosing during GH troughs due to temporary somatostatin-mediated negative feedback. For research consistency, dosing upon waking (when endogenous GH is lowest) and 10–12 hours later produces the most reproducible, interpretable GH response curves.

Injection site (abdomen vs thigh vs deltoid) and technique (subcutaneous depth, injection speed) alter absorption rate (time to Cmax) but not the terminal elimination half-life once systemic circulation is reached. Abdominal subcutaneous injections typically reach peak plasma concentration 5–10 minutes faster than thigh injections due to higher local blood flow and thinner subcutaneous tissue. Intramuscular injection accelerates absorption slightly but increases variability. Regardless of site, the peptide’s 70–80 minute half-life remains constant — clearance is determined by renal elimination, not absorption kinetics.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA